New recommendations for poliovirus vaccination: Combination regimen captures best effects of available vaccines

Postgraduate Medicine

Volumn 102, Issue 5, 1997, Pages 45-62

  Conrad, Dennis A ^a   Jenson, Hal B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; POLIOVAX; TRIPLE VACCINE; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG POTENCY; FEVER; HUMAN; IMMUNITY; INJECTION PAIN; ORAL DRUG ADMINISTRATION; PARALYSIS; POLIOMYELITIS; REVIEW; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0030777916     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.11.366     Document Type: Review

References (15)

1. Kimpen JL, Ogra PL. Poliovirus vaccines: a continuing challenge. Pediatr Clin North Am 1990;37(3):627-49
2. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14(2):568-79
3. Centers for Disease Control and Prevention. Paralytic poliomyelitis: United States, 1980-1994. MMWR 1997;46(4):79-83
4. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR-3):1-25
5. American Academy of Pediatrics Committee on Infectious Diseases. Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. Pediatrics 1997; 99(2):300-5
6. Nomoto A. Recombinant polioviruses as candidates for oral live poliovaccines. Microbiol Immunol 1993;37(3):169-74
7. LaForce FM. Poliomyelitis vaccines: success and controversy. Infect Dis Clin North Am 1990;4(1):75-83
8. Duchene M, Peetermans J, D'Hondt E, et al. Production of poliovirus vaccines: past, present, and future. Viral Immunol 1990;3(4):243-72
9. Rantala H, Cherry JD, Shields WD, et al. Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994;124(2):220-3
10. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Veroproduced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997;16(3):312-22
11. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995; 14(10):835-9
12. McBean AM, Modlin JF. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 1987;6(10):881-7
13. Judelsohn R. Changing the US polio immunization schedule would be bad public health policy. Pediatrics 1996;98(1):115-6
14. Katz SL. Poliovaccine policy: time for a change. Pediatrics 1996;98(1):116-7
15. Centers for Disease Control and Prevention. Progress toward global eradication of poliomyelitis, 1995. MMWR 1996; 45(26):565-8